Author Archives: Kerri Fitzgerald

Outcomes with SLED and CRRT Comparable in Patients with AKI

In a recent small, nonrandomized study, researchers found that clinical outcomes for patients treated with sustained low-efficiency dialysis (SLED) were similar to those for patients treated with continuous renal replacement therapy (CRRT). Abhijat Kitchlu, MD, and colleagues reported study results online in BMC Nephrology [doi:10.1186/s12882-015-0123-4]. CRRT, which permits gradual fluid and solute removal, has been shown to have greater hemodynamic ... Read More »

Midlife Blood Pressure Associated with Late-Life GFR

Factors other than age may account for the high prevalence of chronic kidney disease (CKD) in the elderly. That was among the findings of a cross-sectional analysis of a substudy of a prospective cohort. Results of the analysis were reported by Lesley A. Inker, MD, MS, and colleagues in the American Journal of Kidney Diseases [2015;66(2):240-248]. Among the elderly population, ... Read More »

Measurement of Novel Filtration Markers Strong Surrogate for ESRD Risk

There is a strong association between a >30% decline in kidney function assessed using novel filtration markers and the risk of end-stage renal disease (ESRD). That was among the findings of a cohort study conducted recently by Casey M. Rebholz, PhD, MS, MPH, and colleagues. The researchers reported study findings in the American Journal of Kidney Diseases [2015;66(1):47-54]. In clinical ... Read More »

September 2015: Abstract Roundup

DIABETES Finerenone Improves Urinary-Creatinine Ratio                                              JAMA. 2015;314(9):884-894. For patients with diabetic nephropathy who receive an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB), the addition of the medication finerenone resulted in improvement in albuminuria compared with placebo in a recent study. George L. Bakris, MD, and colleagues designed the study to evaluate the safety and efficacy of varying ... Read More »

Phase 3 CRUISE Trials Find Triferic™ Maintains Hemoglobin without Increasing Ferritin

The phase 3 CRUISE trials, published in Nephrology Dialysis Transplantation, determined that Triferic™ administered via dialysate maintains hemoglobin concentration without increasing ferritin. The randomized, single-blind, placebo-controlled studies examined the safety and efficacy of Triferic™ compared with placebo in patients with chronic hemodialysis. In patients receiving Triferic™, the drug was added to the bicarbonate hemodialysis concentrate, while the placebo cohort receiving ... Read More »

PRIME Study Examines the Safety and Efficacy of Triferic™ in Patients with Chronic Hemodialysis

A recent PRIME study published in Kidney International found that Triferic™ (ferric pyrophosphate citrate) administered via dialysate reduced erythropoiesis-stimulating agent (ESA) requirement compared to placebo while maintaining hemoglobin. This 9-month, prospective, randomized, placebo-controlled, double-blind, multicenter trial sought to determine the safety and efficacy of Triferic™ in a total of 103 patients who were randomized to receive Triferic™ (n=52) or placebo ... Read More »